| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 99,219 | 81,504 | 65,846 | 44,755 |
| Cost of sales | 8,685 | 7,492 | 8,830 | 5,503 |
| Research and development | 19,604 | 19,453 | 17,543 | 19,501 |
| Selling, general and administrative | 62,404 | 69,170 | 64,002 | 58,817 |
| Total operating expenses | 90,693 | 96,115 | 90,375 | 83,821 |
| Income (loss) from operations | 8,526 | -14,611 | -24,529 | -39,066 |
| Other income, net | 2,035 | 2,096 | 2,730 | 4,182 |
| Interest expense | 3,071 | 3,029 | 2,982 | 6,653 |
| Income (loss) before income taxes | 7,490 | -15,544 | -24,781 | -41,537 |
| Provision for income taxes | 80 | 342 | 279 | 0 |
| Net income (loss) | 7,410 | -15,886 | -25,060 | -41,537 |
| Unrealized gain (loss) on marketable securities | 68 | -95 | -137 | 771 |
| Foreign currency translation adjustment | -95 | 200 | 4 | 56 |
| Total other comprehensive income (loss) | -27 | 105 | -133 | 827 |
| Comprehensive income (loss) | 7,383 | -15,781 | -25,193 | -40,710 |
| Basic (in shares) | 127,623,000 | 126,997,000 | 126,036,862 | 124,302,317 |
| Basic (in usd per share) | 0.06 | -0.13 | -0.2 | -0.33 |
| Diluted (in shares) | 132,885,000 | 126,997,000 | 126,036,862 | 124,302,317 |
| Diluted (in usd per share) | 0.06 | -0.13 | -0.2 | -0.33 |
Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. (ARQT)